Vir Biotechnology
218 hedge funds and large institutions have $697M invested in Vir Biotechnology in 2025 Q4 according to their latest regulatory filings, with 33 funds opening new positions, 64 increasing their positions, 80 reducing their positions, and 26 closing their positions.
404% more call options, than puts
Call options by funds: $1.71M | Put options by funds: $340K
67% more funds holding in top 10
Funds holding in top 10: 3 → 5 (+2)
27% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 26
14% more capital invested
Capital invested by funds: $611M → $697M (+$85.5M)
6.02% more ownership
Funds ownership: 77.03% → 83.05% (+6%)
2% more funds holding
Funds holding: 213 → 218 (+5)
20% less repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 80
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
+$8.15M |
| 2 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$6.14M |
| 3 |
State Street
Boston,
Massachusetts
|
+$5.88M |
| 4 |
BCM
Boxer Capital Management
San Diego,
California
|
+$3.72M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
+$3.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SIAU
SB Investment Advisers (UK)
London,
United Kingdom
|
-$21.2M |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$4.24M |
| 3 |
Renaissance Technologies
New York
|
-$3.29M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.85M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$2.64M |
VIR Hedge Fund Activity: Q4 2025 in Review
218 of the 8,266 institutional investors tracked by Wall St. Rank reported a position in Vir Biotechnology (VIR) for Q4 2025, worth a combined $697M — up 14% from $611M a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new VIR positions and 26 closed out — a net gain of 7 holders — while 64 added to existing stakes and 80 trimmed.
The largest buyer was Balyasny Asset Management, opening a new position worth an estimated $8.15M. The largest seller was SB Investment Advisers (UK), cutting an estimated $21.2M.
- 218 institutional investors held Vir Biotechnology (VIR) as of Q4 2025, up from 213 in Q3 2025.
- Funds reported $697M of Vir Biotechnology stock for Q4 2025, up 14% quarter-over-quarter.
- 33 funds opened new Vir Biotechnology positions in Q4 2025 and 26 closed out, a net change of +7 holders.
- The largest Vir Biotechnology buyer in Q4 2025 was Balyasny Asset Management, an estimated $8.15M added.
- The largest Vir Biotechnology seller in Q4 2025 was SB Investment Advisers (UK), an estimated $21.2M sold.
Based on aggregated 13F filings for Q4 2025.